Women were less than half of the people tested for almost all of these common medicines.

High cholesterol

atorvastatin

The most prescribed cholesterol pill; less than 1% of its studies looked at women's results separately.

  • 51.3%

    of the people in the studies were women

  • 57%

    of studies did not allow pregnant women

  • 1%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Not studied

Pregnant women

57% of studies would not let pregnant women join. Only 3 small studies (96 women in all) looked at pregnancy or just after birth.

What do we know?

What the FDA drug label says

Stop taking it when you find out you are pregnant, or ask your doctor. Because of how it works it might harm the baby. It was never tested in pregnant women.

Studies focused on this group (3)

What women report more

Compared with men taking the same medicine.

  • 3.8×Blood sugar problems, including diabetes
  • 2.9×Hormone gland problems
  • 2.8×Changes to the front of the eye
  • 2.2×Calcium, magnesium and bone-mineral problems

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check atorvastatin against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

81,200 people in 170 studies

41,650 womenmiddle line = equal numbers39,550 men

Race

  • White70.6%
  • Asian17.6%
  • Black / African American6.9%
  • Other1.7%
  • More than one race0.9%

Studies didn't say how many of the women were Black, Asian or another race — only totals for everyone.

Hispanic or Latina
9.6%
Age 65 or older
72%
Studies with men only
3
Studies with women only
3
Rules that kept women out

Share of studies with each rule.

  • 57%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    “Pregnancy” NCT02586155
  • 47%

    No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    See the exact rule
    “Patients with evidence of a cardiovascular event in the 12-month pre-index period.” NCT01304641
  • 43%

    No breastfeeding moms

    Women who were breastfeeding could not join.

    See the exact rule
    “Pregnant or lactating women, or women intending to become pregnant” NCT00289900
  • 40%

    No diabetes

    Women with diabetes were turned away.

    See the exact rule
    “Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)” NCT00289900
  • 29%

    Had to use birth control

    Women who couldn't or didn't want to use birth control were turned away.

    See the exact rule
    “…terilization/post-menopausal) or if childbearing potential have neg urine pregnancy test and be willing and able to use non-hormonal birth control (non-hormonal IUD, condom or diaphragm) or remain abstinent from Screening to Follow-up Visit” NCT02586155
  • 28%

    No cancer

    Women with current or past cancer were turned away.

    See the exact rule
    “History of malignancy of any organ syst treated/untreated w/in the past 2 yrs whether or not there is evidence of local recurrence/metastases except localized basal skin cell carcinoma” NCT02586155
What nobody checked

Share of studies that recorded each thing.

  • 1%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 8%
    Body weight (BMI)
  • 21%
    Hispanic / Latina or not
  • 47%
    Race
All 170 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Cardiovascular Events Based On Statin Initiation In The Elderly
NCT01304641
—31,60260.1%
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
NCT02586155
32,41825.6%
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
NCT00289900
32,34055.9%
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
NCT00300430
32,20150.9%
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
NCT01763866
31,89945.9%
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
NCT01154036
31,54752.6%
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
NCT00407537
41,46148%
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
NCT00535405
31,28962.8%
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT01107743
—1,24563.2%
Actual Use Trial of Atorvastatin Calcium 10 mg
NCT01964326
31,23448.1%
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
NCT00479388
31,21648.8%
Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
NCT00409773
31,14343.6%
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
NCT00418834
31,05353.5%
CRESTOR Athero Imaging Head to Head IVUS Study
NCT00620542
31,03926.4%
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
NCT01544309
—1,0180%
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
NCT02476006
399437.1%
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
NCT02662569
398657.2%
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
NCT01516879
390552.4%
Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
NCT00249249
382154%
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
NCT00862251
380847.8%
A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)
NCT00462748
378633.5%
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
NCT00993915
—68741.2%
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
NCT00616772
367632.2%
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
NCT02715726
361525%
Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
NCT00791648
—61530.6%
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
NCT00300469
360951.1%
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
NCT00276484
357939.4%
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
NCT00639158
354255%
A Study of LY3015014 in Participants With High Cholesterol
NCT01890967
251946.4%
Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
NCT00728988
449931.7%
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
NCT03768427
345435.5%
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
NCT00540293
442545.9%
Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia
NCT00683618
341459.4%
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
NCT00309751
341243.4%
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
NCT01370590
340661.1%
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
NCT01953328
340439.6%
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
NCT01105975
239356%
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
NCT01730040
335534.9%
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
NCT00296374
235330.6%
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
NCT02503865
1/235152.4%